The Manila Times

Juniper’s JBS-003 (F-MISO) Program Receives FDA Breakthrough Therapy Designation, Advancing a First-in-Class Hypoxia Tracer Enabling Radiation De-escalation in HPV-Positive ...

Juniper Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole, or FMISO), the first-in-class ...

Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study

Kazia Therapeutics (KZIA) said Tuesday that data showed its paxalisib therapy significantly reduced tumor burden and the total amount of cancer in the body by 52% in a preclinical model of ...

Kazia Therapeutics Expands Paxalisib Trial Into HR+/HER2- Breast Cancer

Kazia Therapeutics (KZIA) said Tuesday that it will expand its ongoing paxalisib clinical trial into hormone receptor-positive, HER2-negative advanced breast cancer after preclinical data showed ...
The Manila Times

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity ...
FT Markets

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in ...
FNArena

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in H

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity ...